Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease

BACKGROUND Although treating to lipid targets ("treat to target") is widely recommended for coronary artery disease (CAD) prevention, some have advocated administering fixed doses of statins based on a person's estimated net benefit ("tailored treatment"). OBJECTIVE To examine how a tailored treatment approach to statin therapy compares with a treat-to-target approach. DESIGN Simulated model of population-level effects of treat-to-target and tailored treatment approaches to statin therapy. DATA SOURCES Statin trials from 1994 to 2009 and nationally representative CAD risk factor data. TARGET POPULATION U.S. persons aged 30 to 75 years with no history of myocardial infarction. TIME HORIZON Lifetime effects of 5 years of treatment. PERSPECTIVE Societal and patient. INTERVENTION Tailored treatment based on a person's 5-year CAD risk (simvastatin, 40 mg, for 5% to 15% CAD risk and atorvastatin, 40 mg, for CAD risk >15%) versus treat-to-target approaches that escalate statin dose per National Cholesterol Education Program [NCEP] III guidelines (including an intensive approach that advances treatment whenever intensification is optional by NCEP III criteria). OUTCOME MEASURES Quality-adjusted life-years (QALYs). RESULTS OF BASE-CASE ANALYSIS Compared with the standard NCEP III approach, the intensive NCEP III approach treated 15 million more persons and saved 570,000 more QALYs over 5 years. The tailored strategy treated a similar number of persons, as did the intensive NCEP III approach, but saved 500,000 more QALYs and treated fewer persons with high-dose statins. RESULTS OF SENSITIVITY ANALYSIS No circumstances were found in which a treat-to-target approach was preferable to tailored treatment. LIMITATION Model assumptions were based on available clinical data, which included few persons 75 years or older. CONCLUSION A tailored treatment strategy prevents more CAD events while treating fewer persons with high-dose statins than low-density lipoprotein cholesterol-based target approaches. Results were robust, even with assumptions favoring a treat-to-target approach. PRIMARY FUNDING SOURCE Department of Veteran Affairs Health Services Research & Development Service's Quality Enhancement Research Initiative.

[1]  B. Davis,et al.  Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. , 1998, Circulation.

[2]  R. Hayward.  All-or-nothing treatment targets make bad performance measures. , 2007, The American journal of managed care.

[3]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[4]  Kevin Weiss,et al.  Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians , 2004, Annals of Internal Medicine.

[5]  N J Wald,et al.  Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[6]  Rodney A Hayward,et al.  Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem , 2006, Annals of Internal Medicine.

[7]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[9]  R. Hayward,et al.  Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease , 2007, Circulation.

[10]  A. Gotto,et al.  Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2000, European heart journal.

[11]  N J Wald,et al.  By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? , 1994, BMJ.

[12]  B. Pitt.  Low-density lipoprotein cholesterol in patients with stable coronary heart disease--is it time to shift our goals? , 2005, The New England journal of medicine.

[13]  C. Furberg,et al.  Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. , 2008, Journal of the American College of Cardiology.

[14]  Mark A Pereira,et al.  Within-person variation in serum lipids: implications for clinical trials. , 2004, International journal of epidemiology.

[15]  Amiram Gafni,et al.  Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. , 2003, Journal of the National Cancer Institute.

[16]  D. Kent,et al.  Reporting clinical trial results to inform providers, payers, and consumers. , 2005, Health affairs.

[17]  M. B. Katan,et al.  Importance of time interval between repeated measurements of total or high-density lipoprotein cholesterol when estimating an individual's baseline concentrations. , 1987, Clinical chemistry.

[18]  K. Anderson,et al.  An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.

[19]  P. Rothwell.  Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.

[20]  B. Squires.  Methods for the Economic Evaluation of Health Care Programmes. , 1987 .

[21]  R. Califf,et al.  An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. , 2002, The American journal of medicine.

[22]  J. Wennberg.  Outcomes Research, Patient Preference, And The Primary Care Physician , 1991, The Journal of the American Board of Family Medicine.

[23]  Sandeep Vijan,et al.  Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians , 2004, Annals of Internal Medicine.

[24]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[25]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[26]  David M Kent,et al.  Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. , 2007, JAMA.

[27]  Richard L Kravitz,et al.  Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. , 2004, The Milbank quarterly.

[28]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[29]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[30]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[31]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[32]  S. van Buuren.  Multiple imputation of discrete and continuous data by fully conditional specification , 2007, Statistical methods in medical research.

[33]  Kirsten Bibbins-Domingo,et al.  Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering , 2009, Annals of Internal Medicine.

[34]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[35]  M. Pencina,et al.  C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study , 2008, Circulation. Cardiovascular quality and outcomes.

[36]  D. Ubbink,et al.  Design and development of a decision aid to enhance shared decision making by patients with an asymptomatic abdominal aortic aneurysm , 2008, Patient preference and adherence.

[37]  N. Paynter,et al.  C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction: The Reynolds Risk Score for Men , 2008, Circulation.

[38]  R. Dudczak,et al.  Effectiveness of coronary heart disease risk management in high‐risk patients , 1994, Clinical cardiology.

[39]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[40]  Donna M. Zulman,et al.  The relative merits of population-based and targeted prevention strategies. , 2008, The Milbank quarterly.

[41]  R. Hayward,et al.  Overestimating outcome rates: statistical estimation when reliability is suboptimal. , 2007, Health services research.

[42]  D. Herrington,et al.  Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease , 2007, Annals of Internal Medicine.

[43]  P. Rothwell,et al.  Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. , 1999, Lancet.

[44]  J. Shepherd.  Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs , 2002, The Lancet.

[45]  Stephane Heritier,et al.  Monitoring Cholesterol Levels: Measurement Error or True Change? , 2008, Annals of Internal Medicine.

[46]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[47]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[48]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[49]  C. Warlow,et al.  Prediction of benefit from carotid endar terectomy in individual patients: a risk-modelling study , 1999, The Lancet.